Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy

This publication has 27 references indexed in Scilit:

• A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma
  Gene Therapy, 2004
• A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
  Cancer Gene Therapy, 2002
• Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma
  The American Journal of Pathology, 2002
• Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
  Journal of Cellular Physiology, 2002
• Adenoviruses in Oncology
  BioDrugs, 2002
• Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers
  Molecular Therapy, 2001
• Thymidine Kinase Gene Therapy for Human Malignant Glioma, Using Replication-Deficient Retroviruses or Adenoviruses
  Human Gene Therapy, 2000
• Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer
  Molecular Therapy, 2000
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
  Nature Medicine, 2000
• Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk
  Molecular Therapy, 2000